These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19242097)

  • 1. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.
    Chang J; Zhao X; Wu X; Guo Y; Guo H; Cao J; Guo Y; Lou D; Yu D; Li J
    Cancer Biol Ther; 2009 Apr; 8(8):676-82. PubMed ID: 19242097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models].
    Shen FB; Yang C; Lei N; Ju Q; Guo Y; Yi B; Luo ZX; Li HX; Wang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):386-90. PubMed ID: 17593813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tumor-selective replication, cytotoxicity and GM-CSF production of oncolytic recombinant adenovirus in KH901 injection].
    Shen FB; Chang JH; Yang C; Li J; Guo Y; Yi B; Li HX; Ye XF; Wang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):31-4. PubMed ID: 17294722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
    Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
    Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor effects of radioiodine labeled KH901 on nude mice bearing hepatoma].
    Mi Y; Li Y; Long Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Apr; 27(2):389-94. PubMed ID: 20481325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of radioiodine-labeled KH901, a tumor-specific oncolytic recombinant adenovirus, in nude mice with human hepatocellular carcinoma.
    Mi YX; Li YC; Long YH
    Nucl Med Commun; 2010 May; 31(5):405-10. PubMed ID: 20147862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
    Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
    Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
    Hu JC; Coffin RS; Davis CJ; Graham NJ; Groves N; Guest PJ; Harrington KJ; James ND; Love CA; McNeish I; Medley LC; Michael A; Nutting CM; Pandha HS; Shorrock CA; Simpson J; Steiner J; Steven NM; Wright D; Coombes RC
    Clin Cancer Res; 2006 Nov; 12(22):6737-47. PubMed ID: 17121894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.
    Harrington KJ; Hingorani M; Tanay MA; Hickey J; Bhide SA; Clarke PM; Renouf LC; Thway K; Sibtain A; McNeish IA; Newbold KL; Goldsweig H; Coffin R; Nutting CM
    Clin Cancer Res; 2010 Aug; 16(15):4005-15. PubMed ID: 20670951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
    Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
    Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
    Bramante S; Koski A; Kipar A; Diaconu I; Liikanen I; Hemminki O; Vassilev L; Parviainen S; Cerullo V; Pesonen SK; Oksanen M; Heiskanen R; Rouvinen-Lagerström N; Merisalo-Soikkeli M; Hakonen T; Joensuu T; Kanerva A; Pesonen S; Hemminki A
    Int J Cancer; 2014 Aug; 135(3):720-30. PubMed ID: 24374597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.
    Burke JM; Lamm DL; Meng MV; Nemunaitis JJ; Stephenson JJ; Arseneau JC; Aimi J; Lerner S; Yeung AW; Kazarian T; Maslyar DJ; McKiernan JM
    J Urol; 2012 Dec; 188(6):2391-7. PubMed ID: 23088985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors.
    Lei N; Shen FB; Chang JH; Wang L; Li H; Yang C; Li J; Yu DC
    Cancer Gene Ther; 2009 Jan; 16(1):33-43. PubMed ID: 18670453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
    Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
    Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma.
    Kim W; Seong J; Oh HJ; Koom WS; Choi KJ; Yun CO
    J Radiat Res; 2011; 52(5):646-54. PubMed ID: 21952320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
    Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
    Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.